A483 greater LOS and 32.3% greater ICU LOS (both p< 0.001) than patients not receiving blood. In patients who received blood, total cost of hospital stay was 22.7% greater including blood product cost and 21.7% greater excluding blood product cost (both p< 0.001). ConClusions: Preventing or rapidly controlling bleeding in patients undergoing complex cardiac surgery would likely reduce patient risk and avoid elevated costs of hospitalization.

A619on naïve and exposed populations was available for colistin and colistin-P, respectively. ConClusions: By conducting an alternative approach where the naïve and exposed arms were considered separate treatment-by-population groups, the full evidence base could be evaluated, including the data for the dry-powder colistimethate sodium inhaler. This will provide relevant information to support clinical decision making in CF.

No abstract

Introduction: Phacoemulsification and manual small incision cataract surgery (MSICS) are sutureless surgeries with low complication rates and satisfactory visual outcomes. Compared to phacoemulsification, MSICS, a cost effective surgical technique, could better suit high volume surgery scenario of resource-poor settings. Objective was to compare preoperative macular thickness of patients undergoing uncomplicated phacoemulsification and MSICS and again postoperatively on days 1, 7 and 40 using optical coherence tomography (OCT). Material and Methods: Randomized study at Rotary Eye Hospital, Malegaon. Patients of age 35-85years having undergone uneventful phacoemulsification or MSICS were included. Patients with co-existing ocular pathologies were excluded. Examination included indirect ophthalmoscopy, slit lamp biomicroscopy with 90 D lens and macular thickness measurements preoperatively and on days 1, 7 and 40postoperatively using OCT. Results: Mean macular thickness in MSICS group was 187.71+/-17.22 μm preoperatively and 201.91+/-18.95μm, 208.04+/-18.66μm, 215.25+/-19.38 μm, postoperatively on days 1, 7 and 40 respectively. Mean macular thickness in phacoemulsification group was 185.77+/-15.64 μm preoperatively and 195.77+/-17.38 μm, 199.05+/-16.87 μm, 203.76 +/-17.48 μm postoperatively on days 1, 7and 40 respectively. Postoperative macular thickness (days 1, 7 and 40) was significantly higher in the MSICS group (p= 0.013, p<0.000 and p<0.000 respectively). There was neither clinical, nor OCT evidence of cystoid macular edema in either group. Conclusion: The subclinical increase in macular thickness was higher following MSICS. However, final visual outcome remained unaffected. For resource-poor settings, MSICS still serves as a good means of offering comparable visual outcomes.

A503(vPDT) fell from 93% to 68%. In the 'without ranibizumab' scenario, only vPDT was administered. Costs of treatment, administration, monitoring, bilateral disease and management of recurrences were included. Results: An estimated 2045 patients were eligible for treatment at year 1 and 2119 at year 5. In the 'with ranibizumab' scenario, 143 patients received ranibizumab at year 1, increasing to 678 at year 5; 1902 patients received vPDT at year 1 and 1441 at year 5. 'With ranibizumab' annual costs were higher in years 1-2 than 'without ranibizumab' costs. During years 3, 4 and 5, cost savings occurred with ranibizumab (£3867, £121 584 and £232 467, respectively), owing to lower total costs of treatment and monitoring than with vPDT. The total 5-year saving 'with ranibizumab' over 'without ranibizumab' was £227 086. ConClusions: Treating visual impairment due to CNV secondary to PM with ranibizumab rather than vPDT is estimated to provide significant cost savings in England and Wales over 5 years.